Mediforum

About Mediforum

Mediforum Co., Ltd. is a South Korean biotechnology company established in 2015, focusing on the research and development of treatments for neurological disorders and other diseases, alongside a portfolio in diagnostics and health supplements. The company is publicly traded on the KOSDAQ exchange.

The core of Mediforum's strategy is the development of pharmaceuticals derived from natural materials. Its leading drug candidate, PM012, is a potential treatment for Alzheimer's disease formulated from seven natural substances. This drug aims to offer a safer alternative to synthetic drugs, with studies suggesting it may help reverse memory loss. As of early 2019, PM012 entered phase 2b and 3 clinical trials in South Korea under the supervision of the Ministry of Food and Drug Safety. The company, led by CEO Kim Chan-gyu as of 2019, has also expressed intentions to pursue FDA clinical trials in the United States. Another significant pipeline candidate is MF-018, a non-narcotic analgesic also derived from natural sources, which has received approval for phase 2 clinical trials in Korea.

In addition to pharmaceuticals, Mediforum operates a diagnostics division. This unit develops and manufactures molecular diagnostic kits, including real-time PCR tests for HPV and STDs, and a genetic test for the ApoE gene associated with dementia risk. This diversification allows the company to generate revenue while pursuing long-term drug development. The business model also encompasses the sale of health supplements and functional foods, such as the 'BrainOne' series for memory support and 'Qurelac' synbiotics for immune health, which are sold directly to consumers. Mediforum has also engaged in partnerships, such as an agreement with the Dementia Relief Center of Gunpo City to provide its supplements as part of a comprehensive patient care program.